Apixaban is a potent, reversible, direct inhibitor of factor Xa. 9 In a phase 2 study, 10 the dose identified as appropriate for testing in phase 3 studies with patients undergoing major joint ...

Mavrakanas TA, Samer CF, Nessim SJ, Frisch G, Lipman ML. Apixaban pharmacokinetics at steady state in hemodialysis patients. J Am Soc Nephrol. 2017;28(7):2241-2248.

WASHINGTON — In patients with atrial fibrillation requiring stroke prevention, the novel factor XIa inhibitor asundexian was associated with lower bleeding rates compared with apixaban ...

For the study, 7 patients received a low dose of apixaban (2.5 mg) twice daily. When the researchers collected blood samples, they found significant accumulation of the drug between day 1 and 8.

There are various regimens for thromboprophylaxis after hip replacement. Low-molecular-weight heparins such as enoxaparin predominantly inhibit factor Xa but also inhibit thrombin to some degree.

Key takeaways: Apixaban tied to less stroke and bleeding in patients with/without dementia vs. dabigatran, rivaroxaban or warfarin. This association was strongest for the outcome of major bleeding.

Rivaroxaban (Xarelto) was also associated with higher risk than apixaban (42.94 vs 20.05 per 1,000 person-years, HR 2.15, 95% CI 1.18-3.94), again with a stronger association in those using ART ...

Bleeding risk does not appear to increase when apixaban is given concomitantly with cardiac P-glycoprotein (P-gp) inhibitors, according to research presented at the 2017 American Heart Association ...

Results of a study comparing apixaban with low-molecular-weight heparin as a treatment to prevent recurrent blood clots in patients with cancer may assuage some of the concern about the bleeding ...

The trial enrolled patients with cryptogenic stroke and evidence suggestive of atrial cardiopathy, but no evidence of atrial fibrillation, who were randomized to apixaban, 5 mg or 2.5 mg twice ...